US3798209A
(en)
|
1971-06-01 |
1974-03-19 |
Icn Pharmaceuticals |
1,2,4-triazole nucleosides
|
USRE29835E
(en)
|
1971-06-01 |
1978-11-14 |
Icn Pharmaceuticals |
1,2,4-Triazole nucleosides
|
US5223263A
(en)
|
1988-07-07 |
1993-06-29 |
Vical, Inc. |
Liponucleotide-containing liposomes
|
US5194654A
(en)
|
1989-11-22 |
1993-03-16 |
Vical, Inc. |
Lipid derivatives of phosphonoacids for liposomal incorporation and method of use
|
US5463092A
(en)
|
1989-11-22 |
1995-10-31 |
Vestar, Inc. |
Lipid derivatives of phosphonacids for liposomal incorporation and method of use
|
US5026687A
(en)
|
1990-01-03 |
1991-06-25 |
The United States Of America As Represented By The Department Of Health And Human Services |
Treatment of human retroviral infections with 2',3'-dideoxyinosine alone and in combination with other antiviral compounds
|
US5210015A
(en)
|
1990-08-06 |
1993-05-11 |
Hoffman-La Roche Inc. |
Homogeneous assay system using the nuclease activity of a nucleic acid polymerase
|
CA2112803A1
(en)
|
1991-07-12 |
1993-01-21 |
Karl Y. Hostetler |
Antiviral liponucleosides: treatment of hepatitis b
|
JP3102945B2
(ja)
|
1992-02-27 |
2000-10-23 |
財団法人野田産業科学研究所 |
肝炎治療剤
|
US5538848A
(en)
|
1994-11-16 |
1996-07-23 |
Applied Biosystems Division, Perkin-Elmer Corp. |
Method for detecting nucleic acid amplification using self-quenching fluorescence probe
|
US5703058A
(en)
|
1995-01-27 |
1997-12-30 |
Emory University |
Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
|
US6391859B1
(en)
|
1995-01-27 |
2002-05-21 |
Emory University |
[5-Carboxamido or 5-fluoro]-[2′,3′-unsaturated or 3′-modified]-pyrimidine nucleosides
|
BR9607109A
(pt)
|
1995-02-01 |
1997-11-04 |
Fraunhofer Ges Forschung |
Emprego de 5'nucleosídeos substituidos para a formação de resisténcia no tratamento de citostáticos e medicamentos contendo estes nucleosídeos
|
GB9505025D0
(en)
|
1995-03-13 |
1995-05-03 |
Medical Res Council |
Chemical compounds
|
DE19514523A1
(de)
|
1995-04-12 |
1996-10-17 |
Schering Ag |
Neue Cytosin- und Cytidinderivate
|
US5858389A
(en)
|
1996-08-28 |
1999-01-12 |
Shaker H. Elsherbini |
Squalene is an antiviral compound for treating hepatitis C virus carriers
|
US6509320B1
(en)
|
1996-10-16 |
2003-01-21 |
Icn Pharmaceuticals, Inc. |
Purine L-nucleosides, analogs and uses thereof
|
DE69721339T2
(de)
|
1996-10-16 |
2004-01-22 |
Ribapharm, Inc., Costa Mesa |
Monozyklische l-nukleoside, analoga und ihre anwendungen
|
CA2266889A1
(en)
|
1996-10-16 |
1998-04-23 |
Guangyi Wang |
Purine l-nucleosides, analogs and uses thereof
|
ES2287971T3
(es)
|
1997-08-11 |
2007-12-16 |
Pfizer Products Inc. |
Dispersiones farmaceuticas solidas con biodisponibilidad incrementada.
|
EP0903148B1
(en)
|
1997-09-21 |
2001-10-10 |
Schering Corporation |
Combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
|
US6201262B1
(en)
|
1997-10-07 |
2001-03-13 |
Cree, Inc. |
Group III nitride photonic devices on silicon carbide substrates with conductive buffer interlay structure
|
US6703374B1
(en)
|
1997-10-30 |
2004-03-09 |
The United States Of America As Represented By The Department Of Health And Human Services |
Nucleosides for imaging and treatment applications
|
BR9907736A
(pt)
|
1998-01-23 |
2000-10-17 |
Newbiotics Inc |
Agentes terapêuticos catalisados por enzima
|
US7462605B2
(en)
|
1998-01-23 |
2008-12-09 |
Celmed Oncology (Usa), Inc. |
Phosphoramidate compounds and methods of use
|
IL138037A0
(en)
|
1998-02-25 |
2001-10-31 |
Univ Emory |
2'-fluoronucleosides
|
US6787305B1
(en)
|
1998-03-13 |
2004-09-07 |
Invitrogen Corporation |
Compositions and methods for enhanced synthesis of nucleic acid molecules
|
US6475985B1
(en)
|
1998-03-27 |
2002-11-05 |
Regents Of The University Of Minnesota |
Nucleosides with antiviral and anticancer activity
|
CN1230198C
(zh)
|
1998-05-15 |
2005-12-07 |
先灵公司 |
给首次接受抗病毒疗法的G慢性丙型肝炎感染患者施用包括利巴韦林和α干扰素的联合疗法
|
EP1087778B1
(en)
|
1998-06-08 |
2005-10-26 |
F. Hoffmann-La Roche Ag |
Use of peg-ifn-alpha and ribavirin for the treatment of chronic hepatitis c
|
GB9816358D0
(en)
|
1998-07-27 |
1998-09-23 |
Angeletti P Ist Richerche Bio |
Enzyme inhibitors
|
AU5475799A
(en)
|
1998-08-10 |
2000-03-06 |
Centre National De La Recherche Scientifique |
Beta-l-2'-deoxy-nucleosides for the treatment of hepatitis
|
GB9821058D0
(en)
|
1998-09-28 |
1998-11-18 |
Univ Cardiff |
Chemical compound
|
CA2354536A1
(en)
|
1998-12-18 |
2000-06-29 |
Schering Corporation |
Ribavirin-pegylated interferon alfa induction hcv combination therapy
|
ATE400252T1
(de)
|
1999-02-10 |
2008-07-15 |
Pfizer Prod Inc |
Pharmazeutische feste dispersionen
|
US6923966B2
(en)
|
1999-04-08 |
2005-08-02 |
Schering Corporation |
Melanoma therapy
|
DE60042073D1
(de)
|
1999-07-22 |
2009-06-04 |
Celmed Oncology Usa Inc |
Enzym katalisierte therapeutische aktivierung
|
CA2389745C
(en)
|
1999-11-04 |
2010-03-23 |
Shire Biochem Inc. |
Method for the treatment or prevention of flaviviridae viral infection using nucleoside analogues
|
US6495677B1
(en)
|
2000-02-15 |
2002-12-17 |
Kanda S. Ramasamy |
Nucleoside compounds
|
PL364995A1
(en)
|
2000-02-18 |
2004-12-27 |
Shire Biochem Inc. |
Method for the treatment or prevention of flavivirus
|
US7094770B2
(en)
|
2000-04-13 |
2006-08-22 |
Pharmasset, Ltd. |
3′-or 2′-hydroxymethyl substituted nucleoside derivatives for treatment of hepatitis virus infections
|
WO2001081359A1
(en)
|
2000-04-20 |
2001-11-01 |
Schering Corporation |
Ribavirin-interferon alfa combination therapy for eradicating detectable hcv-rna in patients having chronic hepatitis c infection
|
MY164523A
(en)
|
2000-05-23 |
2017-12-29 |
Univ Degli Studi Cagliari |
Methods and compositions for treating hepatitis c virus
|
JP2004513070A
(ja)
|
2000-05-26 |
2004-04-30 |
イデニクス(ケイマン)リミテツド |
β−L−2’−デオキシヌクレオシドを用いたデルタ型肝炎ウイルス感染の処置方法
|
US6787526B1
(en)
|
2000-05-26 |
2004-09-07 |
Idenix Pharmaceuticals, Inc. |
Methods of treating hepatitis delta virus infection with β-L-2′-deoxy-nucleosides
|
CN1315862C
(zh)
|
2000-05-26 |
2007-05-16 |
艾登尼科斯(开曼)有限公司 |
处理黄病毒和瘟病毒的方法和组合物
|
MY141594A
(en)
|
2000-06-15 |
2010-05-14 |
Novirio Pharmaceuticals Ltd |
3'-PRODRUGS OF 2'-DEOXY-ß-L-NUCLEOSIDES
|
US6815542B2
(en)
|
2000-06-16 |
2004-11-09 |
Ribapharm, Inc. |
Nucleoside compounds and uses thereof
|
UA72612C2
(en)
|
2000-07-06 |
2005-03-15 |
|
Pyrido[2.3-d]pyrimidine and pyrimido[4.5-d]pyrimidine nucleoside analogues, prodrugs and method for inhibiting growth of neoplastic cells
|
AR029851A1
(es)
|
2000-07-21 |
2003-07-16 |
Dendreon Corp |
Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c
|
AP1466A
(en)
|
2000-07-21 |
2005-09-22 |
Gilead Sciences Inc |
Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same.
|
AR039558A1
(es)
|
2000-08-21 |
2005-02-23 |
Inspire Pharmaceuticals Inc |
Composiciones y metodo para el tratamiento de glaucoma o hipertension ocular
|
US20030008841A1
(en)
|
2000-08-30 |
2003-01-09 |
Rene Devos |
Anti-HCV nucleoside derivatives
|
DE10046541A1
(de)
|
2000-09-19 |
2002-03-28 |
Knoll Ag |
Mechanisch stabile darreichungsformen, enthaltend Ubichinone
|
CN1646141B
(zh)
|
2000-10-18 |
2014-06-25 |
吉利德制药有限责任公司 |
用于治疗病毒感染和异常细胞增殖的修饰核苷类化合物
|
CN1516599A
(zh)
|
2000-10-18 |
2004-07-28 |
���鹫˾ |
病毒唑-聚乙二醇化干扰素α联合治疗慢性传染性丙型肝炎的方法
|
AU2002232660A1
(en)
|
2000-12-15 |
2002-06-24 |
Pharmasset Ltd. |
Antiviral agents for treatment of flaviviridae infections
|
EP1707571B1
(en)
|
2001-01-22 |
2011-09-28 |
Merck Sharp & Dohme Corp. |
Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
|
US7105499B2
(en)
|
2001-01-22 |
2006-09-12 |
Merck & Co., Inc. |
Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
|
GB0112617D0
(en)
|
2001-05-23 |
2001-07-18 |
Hoffmann La Roche |
Antiviral nucleoside derivatives
|
GB0114286D0
(en)
|
2001-06-12 |
2001-08-01 |
Hoffmann La Roche |
Nucleoside Derivatives
|
WO2003000713A1
(en)
|
2001-06-21 |
2003-01-03 |
Glaxo Group Limited |
Nucleoside compounds in hcv
|
JP4455056B2
(ja)
|
2001-07-11 |
2010-04-21 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
架橋二環式セリンプロテアーゼ阻害剤
|
EP2335700A1
(en)
|
2001-07-25 |
2011-06-22 |
Boehringer Ingelheim (Canada) Ltd. |
Hepatitis C virus polymerase inhibitors with a heterobicylic structure
|
WO2003024461A1
(en)
|
2001-09-20 |
2003-03-27 |
Schering Corporation |
Hcv combination therapy
|
US7138376B2
(en)
|
2001-09-28 |
2006-11-21 |
Idenix Pharmaceuticals, Inc. |
Methods and compositions for treating hepatitis C virus using 4'-modified nucleosides
|
ATE370137T1
(de)
|
2001-11-02 |
2007-09-15 |
Glaxo Group Ltd |
4-(6-gliedriger)-heteroaryl-acyl-pyrrolidin derivate als hcv-inhibitoren
|
US7105527B2
(en)
|
2001-12-14 |
2006-09-12 |
Otto Michael J |
N4-acylcytosine nucleosides for treatment of viral infections
|
WO2003051899A1
(en)
|
2001-12-17 |
2003-06-26 |
Ribapharm Inc. |
Deazapurine nucleoside libraries and compounds
|
US20030153744A1
(en)
|
2001-12-21 |
2003-08-14 |
Micrologix Biotech Inc. |
Anti-viral 7-deaza L-nucleosides
|
WO2003062256A1
(en)
|
2002-01-17 |
2003-07-31 |
Ribapharm Inc. |
2'-beta-modified-6-substituted adenosine analogs and their use as antiviral agents
|
RU2278659C9
(ru)
|
2002-02-01 |
2007-02-20 |
Пфайзер Продактс Инк. |
Способ получения гомогенных, высушенных распылением твердых аморфных дисперсий лекарственного средства с использованием модифицированной установки сушки распылением
|
US6642204B2
(en)
|
2002-02-01 |
2003-11-04 |
Boehringer Ingelheim International Gmbh |
Hepatitis C inhibitor tri-peptides
|
PL371593A1
(en)
|
2002-02-01 |
2005-06-27 |
Pfizer Products Inc. |
Method for making homogeneous spray-dried solid amorphous drug dispersions using pressure nozzles
|
US7323453B2
(en)
|
2002-02-13 |
2008-01-29 |
Merck & Co., Inc. |
Methods of inhibiting orthopoxvirus replication with nucleoside compounds
|
WO2003073989A2
(en)
|
2002-02-28 |
2003-09-12 |
Biota, Inc. |
Nucleoside 5'-monophosphate mimics and their prodrugs
|
WO2003072757A2
(en)
|
2002-02-28 |
2003-09-04 |
Biota, Inc. |
Nucleotide mimics and their prodrugs
|
WO2003100017A2
(en)
|
2002-05-24 |
2003-12-04 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides having modified nucleoside units
|
WO2003106477A1
(en)
|
2002-06-01 |
2003-12-24 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds that include carbocyclic nucleosides and their use in gene modulation
|
US7449488B2
(en)
|
2002-06-04 |
2008-11-11 |
Schering Corporation |
Pyrazolopyrimidines as protein kinase inhibitors
|
AU2003251524A1
(en)
|
2002-06-17 |
2003-12-31 |
Isis Pharmaceuticals, Inc. |
Carbocyclic nucleoside analogs as RNA-antivirals
|
EP1551421A2
(en)
|
2002-06-21 |
2005-07-13 |
Merck & Co. Inc. |
Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
|
JP2006512288A
(ja)
|
2002-06-27 |
2006-04-13 |
メルク エンド カムパニー インコーポレーテッド |
Rna依存性rnaウィルスポリメラーゼ阻害薬としてのヌクレオシド誘導体
|
US7456155B2
(en)
|
2002-06-28 |
2008-11-25 |
Idenix Pharmaceuticals, Inc. |
2′-C-methyl-3′-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
|
US7608600B2
(en)
|
2002-06-28 |
2009-10-27 |
Idenix Pharmaceuticals, Inc. |
Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
|
AP2005003211A0
(en)
|
2002-06-28 |
2005-03-31 |
Idenix Cayman Ltd |
1'-,2'-and 3'-modified nucleoside derivatives for treating flaviviridae infections.
|
CN103319554A
(zh)
|
2002-06-28 |
2013-09-25 |
埃迪尼克斯医药公司 |
用于治疗黄病毒感染的修饰的2’和3’-核苷前药
|
EP1525186A1
(en)
|
2002-07-01 |
2005-04-27 |
Pharmacia & Upjohn Company LLC |
Inhibitors of hcv ns5b polymerase
|
US6973905B2
(en)
|
2002-07-01 |
2005-12-13 |
Cinetic Automation Corporation |
Valve lash adjustment apparatus and method
|
CA2489433A1
(en)
|
2002-07-01 |
2004-01-08 |
Pharmacia & Upjohn Company Llc |
Inhibitors of hcv ns5b polymerase
|
JP2005533108A
(ja)
|
2002-07-16 |
2005-11-04 |
メルク エンド カムパニー インコーポレーテッド |
Rna依存性rnaウイルスポリメラーゼの阻害剤としてのヌクレオシド誘導体
|
US7323449B2
(en)
|
2002-07-24 |
2008-01-29 |
Merck & Co., Inc. |
Thionucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
|
CA2493816A1
(en)
|
2002-07-24 |
2004-01-29 |
Ptc Therapeutics, Inc. |
Use of nucleoside compounds for nonsense suppression and the treatment of genetic diseases
|
EP1527082A2
(en)
|
2002-07-25 |
2005-05-04 |
Micrologix Biotech, Inc. |
Anti-viral 7-deaza d-nucleosides and uses thereof
|
TWI244393B
(en)
|
2002-08-06 |
2005-12-01 |
Idenix Pharmaceuticals Inc |
Crystalline and amorphous forms of beta-L-2'-deoxythymidine
|
AU2003261434A1
(en)
|
2002-08-12 |
2004-02-25 |
Bristol-Myers Squibb Company |
Iminothiazolidinones as inhibitors of hcv replication
|
PT1572095E
(pt)
|
2002-09-13 |
2015-10-13 |
Novartis Ag |
Β-l-2'-desoxinucleósidos para tratamento de estirpes resistentes de vhb
|
CA2501547A1
(en)
|
2002-10-15 |
2004-04-29 |
Rigel Pharmaceuticals, Inc. |
Substituted indoles and their use as hcv inhibitors
|
US20040229840A1
(en)
|
2002-10-29 |
2004-11-18 |
Balkrishen Bhat |
Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
|
NZ539727A
(en)
|
2002-11-01 |
2008-01-31 |
Viropharma Inc |
Benzofuran compounds, compositions and methods for treatment and prophylaxis of hepatitis C viral infections and associated diseases
|
US8604183B2
(en)
|
2002-11-05 |
2013-12-10 |
Isis Pharmaceuticals, Inc. |
Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
|
WO2004041889A2
(en)
|
2002-11-05 |
2004-05-21 |
Isis Pharmaceuticals, Inc. |
Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
|
EP1576138B1
(en)
|
2002-11-15 |
2017-02-01 |
Idenix Pharmaceuticals LLC. |
2'-methyl nucleosides in combination with interferon and flaviviridae mutation
|
TWI332507B
(en)
|
2002-11-19 |
2010-11-01 |
Hoffmann La Roche |
Antiviral nucleoside derivatives
|
US7259186B2
(en)
|
2002-12-17 |
2007-08-21 |
Abbott Laboratories |
Salts of fenofibric acid and pharmaceutical formulations thereof
|
US7223785B2
(en)
|
2003-01-22 |
2007-05-29 |
Boehringer Ingelheim International Gmbh |
Viral polymerase inhibitors
|
WO2004080466A1
(en)
|
2003-03-07 |
2004-09-23 |
Ribapharm Inc. |
Cytidine analogs and methods of use
|
WO2004094452A2
(en)
|
2003-04-16 |
2004-11-04 |
Bristol-Myers Squibb Company |
Macrocyclic isoquinoline peptide inhibitors of hepatitis c virus
|
WO2005002626A2
(en)
|
2003-04-25 |
2005-01-13 |
Gilead Sciences, Inc. |
Therapeutic phosphonate compounds
|
WO2004096286A2
(en)
|
2003-04-25 |
2004-11-11 |
Gilead Sciences, Inc. |
Antiviral phosphonate analogs
|
EP1617848A2
(en)
|
2003-04-25 |
2006-01-25 |
Gilead Sciences, Inc. |
Anti-cancer phosphonate conjugates
|
US7470724B2
(en)
|
2003-04-25 |
2008-12-30 |
Gilead Sciences, Inc. |
Phosphonate compounds having immuno-modulatory activity
|
US20050261237A1
(en)
|
2003-04-25 |
2005-11-24 |
Boojamra Constantine G |
Nucleoside phosphonate analogs
|
US7407965B2
(en)
|
2003-04-25 |
2008-08-05 |
Gilead Sciences, Inc. |
Phosphonate analogs for treating metabolic diseases
|
US7452901B2
(en)
|
2003-04-25 |
2008-11-18 |
Gilead Sciences, Inc. |
Anti-cancer phosphonate analogs
|
US20040259934A1
(en)
|
2003-05-01 |
2004-12-23 |
Olsen David B. |
Inhibiting Coronaviridae viral replication and treating Coronaviridae viral infection with nucleoside compounds
|
EP1656093A2
(en)
|
2003-05-14 |
2006-05-17 |
Idenix (Cayman) Limited |
Nucleosides for treatment of infection by corona viruses, toga viruses and picorna viruses
|
US20040229839A1
(en)
|
2003-05-14 |
2004-11-18 |
Biocryst Pharmaceuticals, Inc. |
Substituted nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases
|
ES2726998T3
(es)
|
2003-05-30 |
2019-10-11 |
Gilead Pharmasset Llc |
Análogos de nucleósidos fluorados modificados
|
GB0317009D0
(en)
|
2003-07-21 |
2003-08-27 |
Univ Cardiff |
Chemical compounds
|
RU2006105640A
(ru)
|
2003-07-25 |
2007-09-10 |
Айденикс (Кайман) Лимитед (Ky) |
Аналоги пуриновых нуклеозидов для лечения flaviviridae, включая гепатит с
|
CA2537114C
(en)
|
2003-08-27 |
2012-10-02 |
Biota, Inc. |
Tricyclic nucleosides or nucleotides as therapeutic agents
|
AR045769A1
(es)
|
2003-09-18 |
2005-11-09 |
Vertex Pharma |
Inhibidores de las serina proteasas, particularmente, la proteasa ns3-ns4a del vhc (virus hepatitis c)
|
CA2538252C
(en)
|
2003-09-18 |
2014-02-25 |
Isis Pharmaceuticals, Inc. |
4'-thionucleosides and oligomeric compounds
|
US20050148534A1
(en)
|
2003-09-22 |
2005-07-07 |
Castellino Angelo J. |
Small molecule compositions and methods for increasing drug efficiency using compositions thereof
|
CA2542588A1
(en)
|
2003-10-14 |
2005-04-28 |
Lyco Manufacturing, Inc. |
High speed food product peeling or cleaning machine and method
|
PL1677827T3
(pl)
|
2003-10-27 |
2009-06-30 |
Vertex Pharma |
Połączenia do leczenia HCV
|
US7026339B2
(en)
|
2003-11-07 |
2006-04-11 |
Fan Yang |
Inhibitors of HCV NS5B polymerase
|
TW200528459A
(en)
|
2004-01-06 |
2005-09-01 |
Achillion Pharmaceuticals Inc |
Azabenzofuran substituted thioureas; inhibitors of viral replication
|
WO2005082144A1
(en)
|
2004-02-25 |
2005-09-09 |
Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Office Of Technology Transfer |
Methylation inhibitor compounds
|
EP2423327B1
(en)
|
2004-05-07 |
2014-01-08 |
Celera Corporation |
Genetic polymorphism associated with liver fibrosis methods of detection and uses thereof
|
US8394947B2
(en)
|
2004-06-03 |
2013-03-12 |
Isis Pharmaceuticals, Inc. |
Positionally modified siRNA constructs
|
EP1765416A4
(en)
|
2004-06-03 |
2010-03-24 |
Isis Pharmaceuticals Inc |
DOUBLE-STRANDED COMPOSITIONS COMPRISING DIFFERENTIALLY MODIFIED STRANDS FOR USE IN GENETIC MODULATION
|
WO2005121634A1
(ja)
|
2004-06-08 |
2005-12-22 |
Tokyo Gas Co., Ltd. |
ガス吸着容器
|
BRPI0511900A
(pt)
|
2004-06-08 |
2008-01-22 |
Vertex Pharma |
composições farmacêuticas
|
CA2568379A1
(en)
|
2004-06-15 |
2005-12-29 |
Merck & Co., Inc. |
C-purine nucleoside analogs as inhibitors of rna-dependent rna viral polymerase
|
BRPI0512360A
(pt)
|
2004-06-23 |
2008-03-11 |
Idenix Cayman Ltd |
derivados de 5-aza-7-deazapurina para o tratamento de flaviviridae
|
US20070265222A1
(en)
|
2004-06-24 |
2007-11-15 |
Maccoss Malcolm |
Nucleoside Aryl Phosphoramidates for the Treatment of Rna-Dependent Rna Viral Infection
|
EP2348029A1
(en)
|
2004-07-21 |
2011-07-27 |
Pharmasset, Inc. |
Preparation of alkyl-substituted 2-deoxy-2-fluoro-d-ribofuranosyl pyrimidines and purines and their derivatives
|
CN101023094B
(zh)
|
2004-07-21 |
2011-05-18 |
法莫赛特股份有限公司 |
烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
|
DK2258376T3
(en)
|
2004-07-27 |
2019-04-15 |
Gilead Sciences Inc |
Phosphonate analogues of HIV inhibitor compounds
|
US7153848B2
(en)
|
2004-08-09 |
2006-12-26 |
Bristol-Myers Squibb Company |
Inhibitors of HCV replication
|
US7348425B2
(en)
|
2004-08-09 |
2008-03-25 |
Bristol-Myers Squibb Company |
Inhibitors of HCV replication
|
CN101044151B
(zh)
|
2004-08-23 |
2011-01-19 |
弗·哈夫曼-拉罗切有限公司 |
抗病毒的4'-叠氮基-核苷
|
ATE437875T1
(de)
|
2004-08-23 |
2009-08-15 |
Hoffmann La Roche |
Heterozyklische antivirale verbindungen
|
WO2006029081A2
(en)
|
2004-09-02 |
2006-03-16 |
Neopharm, Inc. |
Nucleoside-lipid conjugates, their method of preparation and uses thereof
|
NZ554442A
(en)
|
2004-09-14 |
2011-05-27 |
Pharmasset Inc |
Preparation of 2'fluoro-2'-alkyl-substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives
|
FR2875409B1
(fr)
|
2004-09-17 |
2010-05-07 |
Sanofi Aventis |
Composition pharmaceutique comprenant une dispersion solide a matrice polymere comprenant une phase continue de polydextrose et une phase continue d'un polymere autre que du polydextrose
|
US20080280850A1
(en)
|
2004-09-24 |
2008-11-13 |
Jean-Pierre Sommadossi |
Methods and Compositions for Treating Flaviviruses, Pestiviruses and Hepacivirus
|
BRPI0516751A
(pt)
|
2004-09-30 |
2008-09-16 |
Tibotec Pharm Ltd |
pirimidinas bicìclicas que inibem hcv
|
AU2005317081A1
(en)
|
2004-10-21 |
2006-06-22 |
Merck & Co., Inc. |
Fluorinated pyrrolo[2,3-d]pyrimidine nucleosides for the treatment of RNA-dependent RNA viral infection
|
CA2585079A1
(en)
|
2004-10-29 |
2006-05-11 |
Biocryst Pharmaceuticals, Inc. |
Therapeutic furopyrimidines and thienopyrimidines
|
US20060110724A1
(en)
|
2004-11-19 |
2006-05-25 |
Burkhardt William Iii |
Quantitative real-time assay for noroviruses and enteroviruses with built in quality control standard
|
EP1674104A1
(en)
|
2004-12-24 |
2006-06-28 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Uridine derivatives as antiviral drugs against a flaviviridae, especially HCV
|
CN100528875C
(zh)
|
2005-02-18 |
2009-08-19 |
美德(江西)生物科技有限公司 |
无结晶型态的印地普隆及其制备方法
|
WO2006093801A1
(en)
|
2005-02-25 |
2006-09-08 |
Abbott Laboratories |
Thiadiazine derivatives useful as anti-infective agents
|
AP2007004128A0
(en)
|
2005-02-28 |
2007-08-31 |
Genelabs Tech Inc |
Tricyclic-nucleoside compounds for treating viral infections
|
AU2006226322B2
(en)
|
2005-03-25 |
2012-03-29 |
Tibotec Pharmaceuticals Ltd. |
Heterobicylic inhibitors of HCV
|
WO2006116557A1
(en)
|
2005-04-25 |
2006-11-02 |
Genelabs Technologies, Inc. |
Nucleoside compounds for treating viral infections
|
WO2006121820A1
(en)
|
2005-05-05 |
2006-11-16 |
Valeant Research & Development |
Phosphoramidate prodrugs for treatment of viral infection
|
AR056347A1
(es)
|
2005-05-12 |
2007-10-03 |
Tibotec Pharm Ltd |
Uso de compuestos de pteridina para fabricar medicamentos y composiciones farmaceuticas
|
US20060276405A1
(en)
|
2005-06-02 |
2006-12-07 |
Schering Corporation |
Methods for treating hepatitis C
|
US8143288B2
(en)
|
2005-06-06 |
2012-03-27 |
Bristol-Myers Squibb Company |
Inhibitors of HCV replication
|
US20060293752A1
(en)
|
2005-06-27 |
2006-12-28 |
Missoum Moumene |
Intervertebral disc prosthesis and associated methods
|
AU2006276246B2
(en)
|
2005-07-25 |
2012-09-27 |
Intermune, Inc. |
Novel macrocyclic inhibitors of hepatitis C virus replication
|
EP1919898B1
(en)
|
2005-07-29 |
2011-01-26 |
Tibotec Pharmaceuticals |
Macrocyclic inhibitors of hepatitis c virus
|
EP1915585A2
(en)
|
2005-07-29 |
2008-04-30 |
Automotive Systems Laboratory Inc. |
Magnetic crash sensor
|
US8012939B2
(en)
|
2005-07-29 |
2011-09-06 |
Tibotec Pharmaceuticals Ltd. Co |
Macrocyclic inhibitors of hepatitis C virus
|
PE20070211A1
(es)
|
2005-07-29 |
2007-05-12 |
Medivir Ab |
Compuestos macrociclicos como inhibidores del virus de hepatitis c
|
BRPI0614621A2
(pt)
|
2005-07-29 |
2011-04-12 |
Tibotec Pharm Ltd |
inibidores macrocìclicos de vìrus da hepatite c
|
MY139923A
(en)
|
2005-07-29 |
2009-11-30 |
Tibotec Pharm Ltd |
Macrocylic inhibitors of hepatitis c virus
|
EP1928475B1
(en)
|
2005-08-15 |
2018-05-23 |
Riboscience LLC |
Antiviral phosphoramidates of 4'-c-azido-substituted pronucleotides
|
CA2904692A1
(en)
|
2005-09-26 |
2007-04-05 |
Gilead Pharmasset Llc |
Modified 4'-nucleosides as antiviral agents
|
EP1957510A1
(en)
|
2005-12-09 |
2008-08-20 |
F.Hoffmann-La Roche Ag |
Antiviral nucleosides
|
AU2006326494A1
(en)
|
2005-12-12 |
2007-06-21 |
Genelabs Technologies, Inc. |
N-(6-membered aromatic ring)-amido anti-viral compounds
|
AU2006330924B2
(en)
|
2005-12-21 |
2012-03-15 |
Abbvie Inc. |
Anti-viral compounds
|
DE602006015861D1
(de)
|
2005-12-21 |
2010-09-09 |
Abbott Lab |
Antivirale verbindungen
|
EP1832281A1
(en)
|
2006-03-10 |
2007-09-12 |
Abbott GmbH & Co. KG |
Process for producing a solid dispersion of an active ingredient
|
AU2007215114A1
(en)
|
2006-02-14 |
2007-08-23 |
Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. |
Nucleoside aryl phosphoramidates for the treatment of RNA-dependent RNA viral infection
|
ES2374455T3
(es)
|
2006-02-17 |
2012-02-16 |
Pfizer Limited |
Derivados de 3-deazapurinza como moduladores de tlr7.
|
JP2009530415A
(ja)
|
2006-03-20 |
2009-08-27 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
医薬組成物
|
US8895531B2
(en)
|
2006-03-23 |
2014-11-25 |
Rfs Pharma Llc |
2′-fluoronucleoside phosphonates as antiviral agents
|
EP2029606B1
(en)
|
2006-05-25 |
2010-05-26 |
Brystol-Myers Squibb Company |
Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors
|
WO2007140200A2
(en)
|
2006-05-25 |
2007-12-06 |
Bristol-Myers Squibb Company |
Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors
|
PT2038290E
(pt)
|
2006-07-07 |
2013-12-10 |
Gilead Sciences Inc |
Moduladores de receptor do tipo toll 7
|
EA019452B1
(ru)
|
2006-07-07 |
2014-03-31 |
Джилид Сайэнс, Инк. |
5-({6-[2,4-БИС-(ТРИФТОРМЕТИЛ)ФЕНИЛ]ПИРИДАЗИН-3-ИЛ}МЕТИЛ)-2-(2-ФТОРФЕНИЛ)-5Н-ИМИДАЗО[4,5-c]ПИРИДИН, СПОСОБ ЕГО ПОЛУЧЕНИЯ, СПОСОБ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ ИНФЕКЦИОННОГО ВИРУСНОГО ГЕПАТИТА С С ЕГО ПОМОЩЬЮ, КОМПОЗИЦИЯ И ЛЕКАРСТВЕННОЕ СРЕДСТВО НА ЕГО ОСНОВЕ
|
CN102532198A
(zh)
|
2006-07-07 |
2012-07-04 |
吉里德科学公司 |
抗病毒的次膦酸酯化合物
|
AU2007275860C1
(en)
|
2006-07-07 |
2014-06-12 |
Gilead Sciences, Inc. |
Modulators of pharmacokinetic properties of therapeutics
|
US8303944B2
(en)
|
2006-08-11 |
2012-11-06 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US7659270B2
(en)
|
2006-08-11 |
2010-02-09 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US7759495B2
(en)
|
2006-08-11 |
2010-07-20 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US8329159B2
(en)
|
2006-08-11 |
2012-12-11 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
CA2666098C
(en)
|
2006-10-10 |
2012-09-25 |
Steven D. Axt |
Preparation of nucleosides ribofuranosyl pyrimidines
|
PL216525B1
(pl)
|
2006-10-17 |
2014-04-30 |
Ct Badań Molekularnych I Makromolekularnych Polskiej Akademii Nauk |
5'-O-[(N-acylo)amidoditiofosforano] nukleozydy oraz sposób wytwarzania 5'-O-[(N-acylo)amidofosforano]-,5'-O-[(N-acylo)amidotiofosforano]-, 5'-O-[(N-acylo)amidoditiofosforano]nukleozydów
|
EP2120565B1
(en)
|
2006-12-20 |
2012-11-28 |
Merck Sharp & Dohme Corp. |
Nucleoside cyclic phosphoramidates for the treatment of rna-dependent rna viral infection
|
US20080261913A1
(en)
|
2006-12-28 |
2008-10-23 |
Idenix Pharmaceuticals, Inc. |
Compounds and pharmaceutical compositions for the treatment of liver disorders
|
EP2124555B1
(en)
|
2007-01-05 |
2015-07-08 |
Merck Sharp & Dohme Corp. |
Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection
|
US7964580B2
(en)
|
2007-03-30 |
2011-06-21 |
Pharmasset, Inc. |
Nucleoside phosphoramidate prodrugs
|
US7741347B2
(en)
|
2007-05-17 |
2010-06-22 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
GB0709791D0
(en)
|
2007-05-22 |
2007-06-27 |
Angeletti P Ist Richerche Bio |
Antiviral agents
|
EP2168959A1
(en)
|
2007-06-19 |
2010-03-31 |
Kyorin Pharmaceutical Co., Ltd. |
Pyridazinone derivative and pde inhibitor containing the same as active ingredient
|
PT2170888E
(pt)
|
2007-06-29 |
2015-08-21 |
Gilead Sciences Inc |
Purina derivados e sua utilização como moduladores de recetor de tipo toll 7
|
EA200971074A1
(ru)
|
2007-06-29 |
2010-08-30 |
Джилид Сайэнс, Инк. |
Антивирусные соединения
|
US8178491B2
(en)
|
2007-06-29 |
2012-05-15 |
Gilead Sciences, Inc. |
Antiviral compounds
|
UA99466C2
(en)
|
2007-07-06 |
2012-08-27 |
Гилиад Сайенсиз, Инк. |
Crystalline pyridazine compound
|
CN101108870A
(zh)
|
2007-08-03 |
2008-01-23 |
冷一欣 |
核苷磷酸酯类化合物及制备方法和应用
|
US7728027B2
(en)
|
2007-08-08 |
2010-06-01 |
Bristol-Myers Squibb Company |
Process for synthesizing compounds useful for treating hepatitis C
|
US8629171B2
(en)
|
2007-08-08 |
2014-01-14 |
Bristol-Myers Squibb Company |
Crystalline form of methyl ((1S)-1-((25)-2-(5-(4'-(2-((25)-1((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate dihydrochloride salt
|
CA2699280A1
(en)
|
2007-09-14 |
2009-03-26 |
Schering Corporation |
Method of treating hepatitis c patients
|
JO2778B1
(en)
|
2007-10-16 |
2014-03-15 |
ايساي انك |
Certain vehicles, installations and methods
|
CL2008003092A1
(es)
|
2007-10-19 |
2009-11-27 |
Abbott Gmbh & Co Kg |
Producto de dispersion solida que comprende a una agente activo derivado de n-aril urea, un agente formador de matriz seleccionado entre ciclodextrinas, polimeros, lipidos y un tensioactivo no ionico; proceso de preparacion de dicho producto de dispersion; y forma dosificacion farmaceutica que lo comprende .
|
DE102007052070A1
(de)
|
2007-10-30 |
2009-05-07 |
Tiefenbacher Pharmachemikalien Alfred E. Tiefenbacher Gmbh & Co. Kg |
Candesartancilexetil
|
JP5238939B2
(ja)
|
2007-11-07 |
2013-07-17 |
三菱化学株式会社 |
長繊維強化複合樹脂組成物および成形品
|
EA201001128A1
(ru)
|
2008-01-11 |
2011-02-28 |
Антариа Лимитед |
Фотозащитные от уф-излучения композиции, прозрачные в видимой области света
|
PT2250163E
(pt)
|
2008-02-12 |
2012-06-01 |
Bristol Myers Squibb Co |
Inibidores do vírus da hepatite c
|
PT2242752E
(pt)
|
2008-02-13 |
2012-10-29 |
Bristol Myers Squibb Co |
Imidazolil bifenil imidazóis como inibidores do vírus da hepatite c
|
US7704992B2
(en)
|
2008-02-13 |
2010-04-27 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US8147818B2
(en)
|
2008-02-13 |
2012-04-03 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US8227431B2
(en)
|
2008-03-17 |
2012-07-24 |
Hetero Drugs Limited |
Nucleoside derivatives
|
US20110130440A1
(en)
|
2008-03-26 |
2011-06-02 |
Alnylam Pharmaceuticals, Inc. |
Non-natural ribonucleotides, and methods of use thereof
|
EP3042660A3
(en)
|
2008-04-15 |
2016-10-26 |
RFS Pharma, LLC. |
Nucleoside derivatives for treatment of caliciviridae infections, including norovirus infections
|
KR20110005869A
(ko)
|
2008-04-15 |
2011-01-19 |
인터뮨, 인크. |
C형 간염 바이러스 복제의 신규한 마크로사이클릭 억제제
|
US8008264B2
(en)
|
2008-04-23 |
2011-08-30 |
Gilead Sciences, Inc. |
1′-substituted carba-nucleoside analogs for antiviral treatment
|
US8173621B2
(en)
|
2008-06-11 |
2012-05-08 |
Gilead Pharmasset Llc |
Nucleoside cyclicphosphates
|
KR20110036609A
(ko)
|
2008-07-10 |
2011-04-07 |
프로시디온 리미티드 |
피페리디닐 gpcr 작용제
|
US7906655B2
(en)
|
2008-08-07 |
2011-03-15 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
WO2010017432A1
(en)
|
2008-08-07 |
2010-02-11 |
Schering Corporation |
Pharmaceutical formulations of an hcv protease inhibitor in a solid molecular dispersion
|
US8383094B2
(en)
|
2008-10-01 |
2013-02-26 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
DE102008057284A1
(de)
|
2008-11-14 |
2010-05-20 |
Ratiopharm Gmbh |
Tabletten enthaltend Lenalidomid und Adhäsionsverstärker
|
US8729077B2
(en)
|
2008-11-28 |
2014-05-20 |
Glaxosmithkline Llc |
Anti-viral compounds, compositions, and methods of use
|
CA2746004C
(en)
|
2008-12-03 |
2017-06-06 |
Presidio Pharmaceuticals, Inc. |
Inhibitors of hcv ns5a
|
WO2010065681A1
(en)
|
2008-12-03 |
2010-06-10 |
Presidio Pharmaceuticals, Inc. |
Inhibitors of hcv ns5a
|
NZ612380A
(en)
|
2008-12-09 |
2015-01-30 |
Gilead Sciences Inc |
Modulators of toll-like receptors
|
CA2748034A1
(en)
|
2008-12-23 |
2010-07-01 |
Pharmasset, Inc. |
Purified 2'-deoxy'2'-fluoro-2'-c-methyl-nucleoside-phosphoramidate prodrugs for the treatment of viral infections
|
PA8855601A1
(es)
|
2008-12-23 |
2010-07-27 |
|
Forformidatos de nucleósidos
|
CN102325783A
(zh)
|
2008-12-23 |
2012-01-18 |
法莫赛特股份有限公司 |
嘌呤核苷的合成
|
BRPI1007027A2
(pt)
|
2009-01-07 |
2019-09-24 |
Scynexis Inc |
combinação de um derivado de ciclosporina e nucleosídeos para tratar do hcv
|
EA201170915A1
(ru)
|
2009-01-09 |
2012-02-28 |
Юниверсити Колледж Оф Кардифф Консалтентс Лимитед |
Фосфорамидатные производные гуанозиновых нуклеозидов для лечения вирусных инфекций
|
WO2010091413A1
(en)
|
2009-02-09 |
2010-08-12 |
Enanta Pharmaceuticals, Inc. |
Linked dibenzimidazole derivatives
|
WO2010096462A1
(en)
|
2009-02-17 |
2010-08-26 |
Enanta Pharmaceuticals, Inc |
Linked diimidazole derivatives
|
TWI438200B
(zh)
|
2009-02-17 |
2014-05-21 |
必治妥美雅史谷比公司 |
C型肝炎病毒抑制劑
|
WO2010094977A1
(en)
|
2009-02-23 |
2010-08-26 |
Arrow Therapeutics Limited |
Novel biphenyl compounds useful for the treatment of hepatitis c
|
US20120040977A1
(en)
|
2009-02-23 |
2012-02-16 |
Presidio Pharmaceuticals, Inc. |
Inhibitors of hcv ns5a
|
CN104478868A
(zh)
*
|
2009-02-27 |
2015-04-01 |
奥索-麦克尼尔-詹森药品公司 |
Hcv大环抑制剂的无定形盐
|
MY160130A
(en)
|
2009-02-27 |
2017-02-28 |
Enanta Pharm Inc |
Hepatitis c virus inhibitors
|
AP2011005929A0
(en)
|
2009-03-20 |
2011-10-31 |
Alios Biopharma Inc |
Substituted nucleoside and nucleotide analogs.
|
JP5913091B2
(ja)
|
2009-03-27 |
2016-04-27 |
メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. |
C型肝炎ウイルス複製の阻害剤
|
WO2010111673A1
(en)
|
2009-03-27 |
2010-09-30 |
Presidio Pharmaceuticals, Inc. |
Substituted bicyclic hcv inhibitors
|
WO2010111534A1
(en)
|
2009-03-27 |
2010-09-30 |
Presidio Pharmaceuticals, Inc. |
Fused ring inhibitors of hepatitis c
|
TWI476190B
(zh)
|
2009-03-30 |
2015-03-11 |
必治妥美雅史谷比公司 |
C型肝炎病毒抑制劑
|
US8796466B2
(en)
|
2009-03-30 |
2014-08-05 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
DE102009015702A1
(de)
|
2009-03-31 |
2010-10-07 |
Ratiopharm Gmbh |
Tabletten enthaltend Dapoxetin und Trockenverarbeitungsverfahren zu deren Herstellung
|
TW201038559A
(en)
|
2009-04-09 |
2010-11-01 |
Bristol Myers Squibb Co |
Hepatitis C virus inhibitors
|
US8143414B2
(en)
|
2009-04-13 |
2012-03-27 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
RU2541571C2
(ru)
|
2009-04-15 |
2015-02-20 |
Эббви Инк. |
Противовирусные соединения
|
MX2011011136A
(es)
|
2009-04-24 |
2011-11-18 |
Tibotec Pharm Ltd |
Eteres diarilicos.
|
CA2760205A1
(en)
|
2009-05-12 |
2010-11-18 |
Schering Corporation |
Fused tricyclic aryl compounds useful for the treatment of viral diseases
|
AP3622A
(en)
|
2009-05-13 |
2016-03-02 |
Gilead Sciences Inc |
Antiviral compounds
|
TWI576352B
(zh)
|
2009-05-20 |
2017-04-01 |
基利法瑪席特有限責任公司 |
核苷磷醯胺
|
US8618076B2
(en)
|
2009-05-20 |
2013-12-31 |
Gilead Pharmasset Llc |
Nucleoside phosphoramidates
|
JP2012528194A
(ja)
|
2009-05-29 |
2012-11-12 |
メルク・シャープ・アンド・ドーム・コーポレーション |
C型肝炎などの疾患を処置するための3つの整列型アリール部分で構成された抗菌性化合物
|
US8138215B2
(en)
|
2009-05-29 |
2012-03-20 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
EP2435424B1
(en)
|
2009-05-29 |
2015-01-21 |
Merck Sharp & Dohme Corp. |
Antiviral compounds composed of three linked aryl moieties to treat diseases such as hepatitis c
|
US8211928B2
(en)
|
2009-05-29 |
2012-07-03 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
DK2455376T3
(en)
|
2009-06-11 |
2015-03-02 |
Abbvie Bahamas Ltd |
Heterocyclic compounds as inhibitors of hepatitis C virus (HCV)
|
US8937150B2
(en)
|
2009-06-11 |
2015-01-20 |
Abbvie Inc. |
Anti-viral compounds
|
US8221737B2
(en)
|
2009-06-16 |
2012-07-17 |
Enanta Pharmaceuticals, Inc. |
Hepatitis C virus inhibitors
|
WO2010148006A1
(en)
|
2009-06-16 |
2010-12-23 |
Enanta Pharmaceuticals, Inc. |
Hepatitis c virus inhibitors
|
WO2011004276A1
(en)
|
2009-07-06 |
2011-01-13 |
Pfizer Limited |
Hepatitis c virus inhibitors
|
SG177516A1
(en)
|
2009-07-13 |
2012-02-28 |
Menicon Co Ltd |
Chitosan hydrogel derivatives as a coating agent with broad spectrum of antimicrobial activities
|
WO2011009084A2
(en)
|
2009-07-16 |
2011-01-20 |
Vertex Pharmaceuticals Incorporated |
Benzimidazole analogues for the treatment or prevention of flavivirus infections
|
EP2467144A1
(en)
|
2009-07-24 |
2012-06-27 |
ViroLogik GmbH |
Combination of proteasome inhibitors and anti-hepatitis medication for treating hepatitis
|
WO2011015658A1
(en)
|
2009-08-07 |
2011-02-10 |
Tibotec Pharmaceuticals |
Bis-benzimidazole derivatives as hepatitis c virus inhibitors
|
EP2462136A1
(en)
|
2009-08-07 |
2012-06-13 |
Janssen R&D Ireland |
Phenyl ethynyl derivatives as hepatitis c virus inhibitors
|
FR2949465B1
(fr)
|
2009-09-01 |
2011-08-12 |
Pf Medicament |
Derives chromones, leur procede de preparation et leurs applications therapeutiques
|
BR112012004969A2
(pt)
|
2009-09-03 |
2019-09-24 |
Tibotec Pharm Ltd |
derivados de bis-benzimidazol
|
JP5795316B2
(ja)
|
2009-09-04 |
2015-10-14 |
ヤンセン ファーマシューティカルズ,インコーポレーテッド |
化合物
|
WO2011031934A1
(en)
|
2009-09-11 |
2011-03-17 |
Enanta Pharmaceuticals, Inc. |
Hepatitis c virus inhibitors
|
US9156818B2
(en)
|
2009-09-11 |
2015-10-13 |
Enanta Pharmaceuticals, Inc. |
Hepatitis C virus inhibitors
|
CA2773772C
(en)
|
2009-09-21 |
2018-06-26 |
Gilead Sciences, Inc. |
2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
|
US8415374B2
(en)
|
2009-10-12 |
2013-04-09 |
Bristol-Myers Squibb Company |
Combinations of hepatitis C virus inhibitors
|
WO2011050146A1
(en)
|
2009-10-23 |
2011-04-28 |
Glaxosmithkline Llc |
Chemical compounds
|
UA108211C2
(uk)
|
2009-11-04 |
2015-04-10 |
Янссен Рід Айрленд |
Бензімідазолімідазольні похідні
|
CN102055717B
(zh)
|
2009-11-09 |
2014-08-13 |
华为技术有限公司 |
快速播放的方法、终端及服务器
|
US20110274648A1
(en)
|
2009-11-11 |
2011-11-10 |
Bristol-Myers Squibb Company |
Hepatitis C Virus Inhibitors
|
US20110269956A1
(en)
|
2009-11-11 |
2011-11-03 |
Bristol-Myers Squibb Company |
Hepatitis C Virus Inhibitors
|
US20110281910A1
(en)
|
2009-11-12 |
2011-11-17 |
Bristol-Myers Squibb Company |
Hepatitis C Virus Inhibitors
|
US20120276047A1
(en)
|
2009-11-25 |
2012-11-01 |
Rosenblum Stuart B |
Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases
|
US20110137633A1
(en)
|
2009-12-03 |
2011-06-09 |
Abbott Laboratories |
Anti-viral compounds and methods of identifying the same
|
EP2512480A4
(en)
|
2009-12-14 |
2013-05-15 |
Enanta Pharm Inc |
HEPATITIS C-VIRUS HEMMER
|
US8377980B2
(en)
|
2009-12-16 |
2013-02-19 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
CN104341401B
(zh)
|
2009-12-18 |
2017-02-15 |
北京凯因科技股份有限公司 |
C型肝炎病毒复制的新型抑制剂
|
AR079528A1
(es)
|
2009-12-18 |
2012-02-01 |
Idenix Pharmaceuticals Inc |
Inhibidores de arileno o heteroarileno 5,5-fusionado del virus de la hepatitis c
|
CA2785488A1
(en)
|
2009-12-22 |
2011-07-21 |
Merck Sharp & Dohme Corp. |
Fused tricyclic compounds and methods of use thereof for the treatment of viral diseases
|
WO2011079327A1
(en)
|
2009-12-24 |
2011-06-30 |
Vertex Pharmaceuticals Incorporated |
Analogues for the treatment or prevention of flavivirus infections
|
US8362020B2
(en)
|
2009-12-30 |
2013-01-29 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
PT2523950T
(pt)
|
2010-01-15 |
2017-06-01 |
Gilead Sciences Inc |
Inibidores dos vírus flaviridae
|
WO2011091446A1
(en)
|
2010-01-22 |
2011-07-28 |
Glaxosmithkline Llc |
Chemical compounds
|
MA34147B1
(fr)
|
2010-03-09 |
2013-04-03 |
Merck Sharp & Dohme |
Composes tricycliques fusionnes de silyle et leurs methodes d'utilisation dans le cadre du traitement de maladies virales
|
TW201136945A
(en)
|
2010-03-31 |
2011-11-01 |
Pharmasset Inc |
Purine nucleoside phosphoramidate
|
SG184323A1
(en)
|
2010-03-31 |
2012-11-29 |
Gilead Pharmasett Llc |
Stereoselective synthesis of phosphorus containing actives
|
US8563530B2
(en)
|
2010-03-31 |
2013-10-22 |
Gilead Pharmassel LLC |
Purine nucleoside phosphoramidate
|
CN102869792A
(zh)
|
2010-04-13 |
2013-01-09 |
弗·哈夫曼-拉罗切有限公司 |
预测hcv治疗中的早期病毒学应答
|
WO2011146401A1
(en)
|
2010-05-17 |
2011-11-24 |
Intermune, Inc. |
Novel inhibitors of hepatitis c virus replication
|
NZ603310A
(en)
|
2010-05-21 |
2015-01-30 |
Gilead Sciences Inc |
Heterocyclic flaviviridae virus inhibitors
|
TW201201815A
(en)
|
2010-05-28 |
2012-01-16 |
Gilead Sciences Inc |
1'-substituted-carba-nucleoside prodrugs for antiviral treatment
|
NZ605440A
(en)
*
|
2010-06-10 |
2014-05-30 |
Abbvie Bahamas Ltd |
Solid compositions comprising an hcv inhibitor
|
WO2011156757A1
(en)
*
|
2010-06-10 |
2011-12-15 |
Gilead Sciences, Inc. |
Combination of anti-hcv compounds with ribavirin for the treatment of hcv
|
JP5937073B2
(ja)
|
2010-07-19 |
2016-06-22 |
ギリード・サイエンシズ・インコーポレーテッド |
ジアステレオマーとして純粋なホスホルアミデートプロドラッグの調製方法
|
CA2809261A1
(en)
|
2010-08-26 |
2012-03-01 |
Rfs Pharma, Llc |
Potent and selective inhibitors of hepatitis c virus
|
JP2013538230A
(ja)
|
2010-09-20 |
2013-10-10 |
ギリアード サイエンシーズ, インコーポレイテッド |
抗ウイルス治療用の2’−フルオロ置換カルバヌクレオシド類似体
|
BR112013007696A2
(pt)
|
2010-09-29 |
2019-09-24 |
Merck Sharp & Dohme |
composto, composição farmacêutica, usos do referido composto e da referida composição
|
WO2012048421A1
(en)
|
2010-10-14 |
2012-04-19 |
Boehringer Ingelheim International Gmbh |
Hepatitis c inhibitor compounds
|
US20120107278A1
(en)
|
2010-10-29 |
2012-05-03 |
Pharmasset, Inc. |
Abbreviated hcv therapy for hcv infected patients with il28b c/c genotype
|
TWI640526B
(zh)
|
2010-11-17 |
2018-11-11 |
基利法瑪席特有限責任公司 |
抗病毒化合物
|
CA2818853A1
(en)
|
2010-11-30 |
2012-06-07 |
Gilead Pharmasset Llc |
2'-spirocyclo-nucleosides for use in therapy of hcv or dengue virus
|
JP5891241B2
(ja)
|
2010-12-20 |
2016-03-22 |
ギリアード サイエンシーズ, インコーポレイテッド |
Hcvを処置するための組合せ
|
WO2012087976A2
(en)
|
2010-12-21 |
2012-06-28 |
Intermune, Inc. |
Novel inhibitors of hepatitis c virus replication
|
EP2694078A1
(en)
|
2011-03-31 |
2014-02-12 |
F.Hoffmann-La Roche Ag |
Selection of hcv treatment
|
US8655250B2
(en)
|
2011-03-31 |
2014-02-18 |
Xerox Corporation |
Apparatus and method for marking material fix level control in a printing apparatus
|
JP2014520772A
(ja)
|
2011-06-30 |
2014-08-25 |
ステラ・アンパルトセルスカブ |
Hcv併用療法
|
EP2562223A1
(de)
|
2011-08-26 |
2013-02-27 |
Sika Technology AG |
Zweikomponentige Zusammensetzung auf Basis von silanfunktionellen Polymeren
|
MX354958B
(es)
|
2011-09-16 |
2018-03-27 |
Gilead Pharmasset Llc |
Metodos para el tratamiento de vhc.
|
DE202012012956U1
(de)
|
2011-10-21 |
2014-10-16 |
Abbvie Inc. |
Kombination aus mindestens zwei direkt wirkenden antiviralen Wirkstoffen für die Verwendung zur Behandlung von HCV, umfassend Ribavirin aber nicht Interferon
|
UY34401A
(es)
|
2011-10-21 |
2013-05-31 |
Abbvie Inc |
Métodos para el tratamiento de hcv
|
US8492386B2
(en)
|
2011-10-21 |
2013-07-23 |
Abbvie Inc. |
Methods for treating HCV
|
US8466159B2
(en)
|
2011-10-21 |
2013-06-18 |
Abbvie Inc. |
Methods for treating HCV
|
BR112014010295A2
(pt)
|
2011-10-31 |
2017-04-18 |
Gilead Pharmassett Llc |
métodos e composições para o tratamento de vírus de hepatite c
|
US20130109647A1
(en)
|
2011-10-31 |
2013-05-02 |
Gilead Pharmasset Llc |
Methods and compositions for treating hepatitis c virus
|
ME02196B
(me)
|
2011-11-16 |
2016-02-20 |
Gilead Pharmasset Llc |
Kondenzovani imidazolilimidazoli kao antiviralna jedinjenja
|
US8889159B2
(en)
*
|
2011-11-29 |
2014-11-18 |
Gilead Pharmasset Llc |
Compositions and methods for treating hepatitis C virus
|
PE20141296A1
(es)
|
2011-11-29 |
2014-10-08 |
Gilead Pharmasset Llc |
Composiciones y metodos para tratar el virus de la hepatitis c
|
EP2907505A3
(en)
|
2011-12-29 |
2015-12-30 |
Abbvie Inc. |
Solid compositions comprising an HCV inhibitor
|
US9034832B2
(en)
|
2011-12-29 |
2015-05-19 |
Abbvie Inc. |
Solid compositions
|
EP2802597A1
(en)
|
2012-01-13 |
2014-11-19 |
Gilead Pharmasset LLC |
Crysral structure of hcv polymerase complexes and methods of use
|
WO2013177188A1
(en)
|
2012-05-22 |
2013-11-28 |
Idenix Pharmaceuticals, Inc. |
3',5'-cyclic phosphoramidate prodrugs for hcv infection
|
US8969588B2
(en)
|
2012-06-05 |
2015-03-03 |
Gilead Pharmasset Llc |
Solid forms of an antiviral compound
|
US9056860B2
(en)
|
2012-06-05 |
2015-06-16 |
Gilead Pharmasset Llc |
Synthesis of antiviral compound
|
AR091279A1
(es)
|
2012-06-08 |
2015-01-21 |
Gilead Sciences Inc |
Inhibidores macrociclicos de virus flaviviridae
|
UA119315C2
(uk)
|
2012-07-03 |
2019-06-10 |
Гіліад Фармассет Елелсі |
Інгібітори вірусу гепатиту с
|
US8841340B2
(en)
|
2012-08-17 |
2014-09-23 |
Gilead Sciences, Inc. |
Solid forms of an antiviral compound
|
TW201446286A
(zh)
|
2013-01-31 |
2014-12-16 |
Gilead Pharmasset Llc |
抗病毒化合物之固態分散調製劑
|
PL2950786T3
(pl)
|
2013-01-31 |
2020-05-18 |
Gilead Pharmasset Llc |
Formulacja skojarzona dwóch związków przeciwwirusowych
|
WO2014137929A1
(en)
|
2013-03-04 |
2014-09-12 |
Gilead Pharmasset Llc |
Methods for treating hepatitis c virus
|
US20140343008A1
(en)
|
2013-05-16 |
2014-11-20 |
Gilead Pharmasset Llc |
Hepatitis c treatment
|